Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in untreated CLL/SLL
NCT01113632Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2010
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by SCRI Development Innovations. Started Jul 2010; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01113632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113632.